Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which automated insulin pump keeps blood sugar tightest? study pits top systems Head-to-Head

NCT ID NCT06834334

Knowledge-focused Sponsor: Castilla-La Mancha Health Service Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 189 adults with type 1 diabetes who used one of three advanced hybrid closed-loop insulin pump systems: Medtronic Minimed 780G, Tandem T Slim X2, or CamAPS Fx. The goal was to see which system helped patients keep their blood sugar in a very tight range (70-140 mg/dL) for the longest time each day. Researchers also measured time in standard range, time above and below range, and other glucose control metrics. Since this is an observational study, it provides real-world insights but cannot prove one system is definitively better than another.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Advanced hybrid closed-loop systems (Medtronic Minimed 780G, Tandem T Slim X2, CamAPS Fx)
What this could lead to
If successful, this study could show which automated insulin pump system helps people with type 1 diabetes keep their blood sugar in a very tight healthy range, potentially reducing long-term complications.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by patient differences. It also only looks at short-term glucose data, not long-term health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

189 people

The number who actually took part.

Started

Feb 2025

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with type 1 diabetes treated with AHCL attended in any of the three centers.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with type 1 diabetes. * Age greater than or equal to 18 years. * Treated with advanced hybrid closed-loop systems (AHCL) for at least 3 months * Actived continuous glucose monitoring data in the last 14 days. Exclusion Criteria: * Other types of diabetes. * Receiving treatment with insulin regimens other than AHCL. * Having received AHCL treatment for less than 3 months in a row prior to inclusion in the study with the same system. * No data on use of the AHCL system during the previous 14 days. * Severe or uncontrolled psychiatric disorder. * Pregnancy or end of pregnancy less than 3 months ago or preparation for pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes (T1D) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes (T1D)

Contacts and locations

Locations

  • Badajoz University Hospital

    Badajoz, Badajoz, 06080, Spain

  • Ciudad Real General University Hospital

    Ciudad Real, Ciudad Real, 13005, Spain

  • Hospital Universitario Mutua de Tarrasa

    Terrassa, Barcelona, 08221, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.